THOMAS JAMES DOYLE - 02 Jan 2025 Form 4 Insider Report for Kura Oncology, Inc. (KURA)

Role
SVP, Finance & Accounting
Signature
Teresa Bair, Attorney-in-fact for Thomas Doyle
Issuer symbol
KURA
Transactions as of
02 Jan 2025
Net transactions value
$0
Form type
4
Filing time
06 Jan 2025, 16:09:05 UTC
Previous filing
31 Jan 2024
Next filing
28 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KURA Common Stock Award $0 +21,250 +42% $0.000000 71,892 02 Jan 2025 Direct F1, F2
transaction KURA Common Stock Award $0 +21,250 +30% $0.000000 93,142 02 Jan 2025 Direct F3
holding KURA Common Stock 500 02 Jan 2025 spouse's 401(k)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KURA Option to purchase common stock Award $0 +42,500 $0.000000 42,500 02 Jan 2025 Common Stock 42,500 $8.68 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/26, 1/26/27, 1/26/28 and 1/26/29.
F2 Includes 2,499 shares acquired on May 17, 2024 and 50 shares acquired on November 17, 2024 pursuant to the Issuer's Employee Stock Purchase Plan.
F3 Grant of RSUs. The RSUs vest in full on 1/26/27.
F4 This option vests in 48 equal monthly installments commencing on the grant date.